Sight Diagnoses Covid-19 Blood

Sight Diagnostics has announced a collaboration with Sheba Medical Center near Tel Aviv to mitigate the risk of contamination by COVID-19.

Sight’s OLO blood analyser will provide rapid complete blood count (CBC) results in a dedicated lab to process samples of COVID-19 patients who are being monitored and treated in a separate field hospital.

Sight Diagnostics uses advanced computer-vision and machine-learning technology in the field of blood diagnostics. The company’s initial product, the Parasight platform, is a highly accurate, easy-to-use device for diagnosing malaria.

Sight Diagnostics is also applying its technology to the complete blood count (CBC) market, developing a point-of-care CBC platform that will provide a five-point differential blood count for use in doctors’ offices and emergency medical centers.

Beyond its malaria and CBC platforms, the company’s computer-vision technology has the potential to unlock advanced diagnostic approaches to numerous additional diseases and provide patients with accurate and inexpensive testing.

In December 2019, the company received FDA 510(k) clearance for its OLO analyzer, a device that performs blood tests and provides lab-grade results in minutes. Tests include the complete blood count (CBC) panel, which comprises the most common and useful tests conducted by medical professionals.Read LessCombating Coronavirus Pandemic

Written by

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam libero diam, elementum eget porttitor at, tincidunt at nulla.